CSL Ltd ASX:CSL:
TO CEASE NEW PATIENT INITIATION FOR TAVNEOS IN EU AND EEA MARKETS
EMA CHMP RECOMMENDS REVOCATION OF EU MARKETING AUTHORISATION FOR TAVNEOS ON JUN 26
TO PROVIDE DETAILS ON TAVNEOS IP IMPAIRMENT IN 2026 FULL YEAR RESULTS
EXPECTS FY26 TAVNEOS SALES REVENUE OF ABOUT $145 MILLION